Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biogena Group Invest AGWBO:BIO 59 Debt-to-EBITDA is 0.00 as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 59/100 and a GF Value™ of €3.54 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,571 Consumer Packaged Goods companies, Biogena Group Invest AG ranks worse than 63653.66% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Biogena Group Invest AG's Debt-to-EBITDA or its related term are showing as below:
WBO:BIO's Debt-to-EBITDA is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 2.11 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Biogena Group Invest AG Debt-to-EBITDA Related Terms
Biogena Group Invest AG Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:BIO vs KHC, GIS, MKC: Debt-to-EBITDA Comparison
For the Packaged Foods subindustry, Biogena Group Invest AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Jan. 2026) EBITDA data.
Biogena Group Invest AG (WBO:BIO) has a Debt-to-EBITDA of 0.00 as of Jan. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biogena Group Invest AG. According to the industry distribution chart, Biogena Group Invest AG ranks #999999 out of 1571 companies in the Consumer Packaged Goods industry.
Is Biogena Group Invest AG's Debt-to-EBITDA too high?
Biogena Group Invest AG's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Biogena Group Invest AG ranks #999999 out of 1571 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Biogena Group Invest AG has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #999999 out of 1571 companies for Debt-to-EBITDA. This places Biogena Group Invest AG in the lower half of its industry. The industry median Debt-to-EBITDA is 2.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.11, based on 1,571 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Biogena Group Invest AG. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.54, compared to a current price of €5.35 — trading 51.1% above its estimated fair value. The current Debt-to-EBITDA is 0.00. Biogena Group Invest AG's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Debt-to-EBITDA is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €5.35 is trading 51.1% above its estimated GF Value™ of €3.54.
GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.
Key valuation signals for WBO:BIO:
Debt-to-EBITDA: 0.00
GF Value™: €3.54 vs. price of €5.35 (51.1% above fair value)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
59GF Score
Get the complete analysis for WBO:BIO
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 
